索磷布韦在终末期肾病行血液透析治疗合并急性丙型肝炎患者中的安全性和有效性
Safety and efficacy of sofosbuvir-based treatment of acute hepatitis C in end-stage renal disease patients undergoing hemodialysis

摘要：目的 评估索磷布韦为基础的治疗方案在终末期肾病行血液透析治疗合并急性丙型肝炎患者群体中应用的安全性和有效性。方法 纳入33位研究对象持续接受半量索磷布韦(200mg)联合全量达卡他韦(90mg)治疗24周，于治疗第0、4、8、12、16、20、24、28、32和36周分别检测血清HCV RNA、ALT、TBil水平，并评估药物相关不良反应。结果 所有患者均在治疗结束后12周达到了持续病毒学反应(sustained virologic responses, SVRs)，并且无药物相关的严重不良事件出现。结论 半量索磷布韦(200mg)联合全量达卡他韦(90mg)的治疗对于终末期肾脏疾病行血液透析合并急性丙型肝炎的患者有效且安全。
ABSTRACT: Objective To evaluate the safety and efficacy of sofosbuvir-based therapy in end-stage renal disease patients undergoing hemodialysis complicated with acute hepatitis C. Methods Totally 33 subjects who met the inclusion criteria received a half dose of sofosbuvir (200mg) and a full dose of daclatasvir (90mg) daily for 24 weeks. Then we detected the levels of HCV RNA, ALT, and TBil at 0, 4, 8, 12, 16, 20, 24, 28, 32 and 36 weeks respectively and evaluated the adverse drug reactions. Results All the patients made a sustained virological response at 12 weeks after the end of treatment, and there were no drug-related serious adverse events. Conclusion A half dose of sofosbuvir (200mg once daily) plus a full dose of daclatasvir (90mg once daily) was safe and effective for treatment of acute HCV infection in patients who were undergoing ESRD and were on hemodialysis